Meeting
2023 ASCO Quality Care Symposium
Non-elective inpatient anti-cancer therapy for solid tumors: To treat or not to treat?
Authors
Chloe Shevlin
35 Park St, New Haven, CT
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Health Care Access, Equity, and Disparities,Technology and Innovation in Quality of Care,Palliative and Supportive Care
Sub Track
End-of-Life Care
Citation
JCO Oncol Pract 19, 2023 (suppl 11; abstr 234)
DOI
10.1200/OP.2023.19.11_suppl.234
Abstract #
234
Poster Bd #
G15
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Annual Meeting
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
First Author: Nehal J. Lakhani
Poster
2022 ASCO Annual Meeting
Safety, pharmacodynamic, and clinical response evaluation of nilotinib and paclitaxel in adults with refractory solid tumors.
First Author: Sarah Shin
First Author: Giulia Petrone
Poster
2022 ASCO Annual Meeting
Phase 1b study of GS-3583, a novel FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.
First Author: Anthony W. Tolcher